Altimmune, Inc.
ALTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAltimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. The company carries a $585.4M market cap, placing it firmly in the small-cap category. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Market Cap
$585.4M
Beta
0.17
P/E (TTM)
—
P/E (Fwd)
-3.34
EPS (TTM)
$-0.92
EPS (Fwd)
$-0.90
ROE
-42.8%
ROA
-24.4%
Cash
$331.5M
Total Debt
$35.8M
Free CF
-$42.5M
52W Change
-44.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $331.5M in cash comfortably exceeding the $35.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$42.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from -$68K (2022) to $41K (2025), reflecting a 160% increase over the period.
The relatively low beta of 0.17 suggests ALT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ALT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.